Significance of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1 (PAI-1) Expression in Human Colorectal Carcinomas

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Tumor Biology

• Publication date

  2002-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000064033PMID 12218297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.

  2001cited by this paper
• Expression of Gelatinase-A (MMP-2) in Human Colon Cancer and Normal Colon Mucosa

  2001cited by this paper
• Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer

  2000cited by this paper
• The plasminogen activation system in tumor growth, invasion, and metastasis

  2000cited by this paper
• Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

  2000cited by this paper
• The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

  2000cited by this paper
• Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets

  2000cited by this paper
• Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.

  2000cited by this paper
• Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.

  1999cited by this paper
• Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.

  1999cited by this paper
• Urokinase plasminogen activator: A prognostic marker in multiple types of cancer

  1999cited by this paper
• Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size

  1999cited by this paper
• Tumour markers of prognosis in colorectal cancer

  1999cited by this paper
• The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.

  1998cited by this paper
• Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.

  1998cited by this paper
• The urokinase‐type plasminogen activator system in cancer metastasis: A review

  1997cited by this paper
• Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study.

  1997cited by this paper
• Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor‐1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues

  1996cited by this paper
• Proteases as prognostic markers in cancer.

  1996cited by this paper
• Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.

  1995cited by this paper
• Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report

  1995cited by this paper
• Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

  1994cited by this paper
• Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.

  1994cited by this paper
• Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

  1994cited by this paper
• Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas

  1993cited by this paper
• Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues.

  1993cited by this paper
• The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion

  1992cited by this paper
• Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?

  1992cited by this paper
• Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

  1991cited by this paper
• Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

  1991cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors

  2020cites this paper
• Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

  2018cites this paper
• Role of ZEB1 in Tumor Progression: Regulation of Cell Invasion and Senescence

  2017cites this paper
• The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions

  2015cites this paper
• Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

  2014cites this paper
• Der Einfluss von Hypoxie auf die Expression von Komponenten des Plasminogen-Aktivierungs-Systems und den Vascular Endothelial Growth Factor in Plattenepithelkarzinomzelllinien des Kopf-Hals-Bereiches.

  2013influential citation
• Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance

  2013cites this paper
• CCR-12-2675 R 2 ZEB 1 promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1

  2013influential citation
• Effects of miR-193a and sorafenib on hepatocellular carcinoma cells

  2013cites this paper
• ZEB1 Promotes Invasiveness of Colorectal Carcinoma Cells through the Opposing Regulation of uPA and PAI-1

  2013cites this paper
• Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms

  2013cites this paper
• Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.

  2011cites this paper
• Molecular changes consistent with increased proliferation and invasion are common in rectal cancer

  2011cites this paper
• Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.

  2011cites this paper
• The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO2 pneumoperitoneum

  2010cites this paper
• Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-γ and Plasminogen Activator Inhibitor-1

  2009cites this paper
• Differential Prognostic Impact of uPA and PAI-1 in Colon and Rectal Cancer

  2009cites this paper
• PPAR-gamma ligands and adipocytes regulate expression of the plasminogen activator system in breast cancer

  2009cites this paper
• 消化管癌におけるPlasminogen activator inhibitor-1過剰発現の検討

  2006cites this paper
• Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression

  2006cites this paper
• Indication of a role of plasminogen activator inhibitor type 1 in protecting murine fibrosarcoma cells against apoptosis

  2005cites this paper
• Clinical study of t-PA and u-PA expression in patients with gastrointestinal cancer

  2005cites this paper
• Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone.

  2004cites this paper
• University of Groningen Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells

  2004cites this paper
• Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma.

  2004cites this paper
• Binding and fate of plasminogen activator inhibitor type-2 in breast carcinoma cells: rationale for development as a delivery vehicle of cytotoxins for anti-urokinase therapeutic strategies

  2004cites this paper
• Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells

  2004cites this paper
• Analysis of genes associated with lymphatic metastasis in pancreatic carcinoma using cDNA microarray

  2003cites this paper
• Theme Issue: Update on the role of the fibrinolysis/ plasminogen activation system in a cellular context

  2003cites this paper